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Abstract
Progranulin (PGRN) is predominantly expressed by microglia in the
brain, and genetic and experimental evidence suggests a critical
role in Alzheimer’s disease (AD). We asked whether PGRN expres-
sion is changed in a disease severity-specific manner in AD. We
measured PGRN in cerebrospinal fluid (CSF) in two of the best-
characterized AD patient cohorts, namely the Dominant Inherited
Alzheimer’s Disease Network (DIAN) and the Alzheimer’s Disease
Neuroimaging Initiative (ADNI). In carriers of AD causing dominant
mutations, cross-sectionally assessed CSF PGRN increased over the
course of the disease and significantly differed from non-carriers
10 years before the expected symptom onset. In late-onset AD,
higher CSF PGRN was associated with more advanced disease
stages and cognitive impairment. Higher CSF PGRN was associated
with higher CSF soluble TREM2 (triggering receptor expressed on
myeloid cells 2) only when there was underlying pathology, but
not in controls. In conclusion, we demonstrate that, although CSF
PGRN is not a diagnostic biomarker for AD, it may together with
sTREM2 reflect microglial activation during the disease.
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Introduction
Haploinsufficiency of the gene encoding progranulin (PGRN) leads
to frontotemporal lobar degeneration (FTLD) with TAR DNA bind-
ing protein 43 (TDP-43) deposition (FTLD-TDP) (Baker et al, 2006;
Cruts et al, 2006; Neumann et al, 2006). Reduced PGRN protein in
plasma, serum or cerebrospinal fluid (CSF) has been shown to be a
reliable diagnostic biomarker for early detection of progranulin
(GRN) mutation carriers (Ghidoni et al, 2008; Finch et al, 2009;
Sleegers et al, 2009). Certain GRN variants may also increase the
risk for Alzheimer’s disease (AD) (Brouwers et al, 2008; Rademak-
ers et al, 2008; Viswanathan et al, 2009; Lee et al, 2011; Cruchaga
et al, 2012; Sheng et al, 2014; Xu et al, 2017), yet associations could
not be confirmed in some other studies (Fenoglio et al, 2009; Mateo
et al, 2013). Studies in AD mouse models indicated that PGRN is
strongly increased in microglia clustering around amyloid plaques
(Pereson et al, 2009) and may also affect amyloid b-peptide (Ab)
and tau deposition. PGRN may have beneficial effects on Ab deposi-
tion, since PGRN deficiency in animal models increases Ab deposi-
tion (Minami et al, 2014) and elevating PGRN expression reduces
the amyloid plaque burden (Minami et al, 2014; Van Kampen &
Kay, 2017). However, it has also been observed that PGRN defi-
ciency leads to a decrease in diffuse Ab plaque load (Takahashi
et al, 2017; Hosokawa et al, 2018), which may point to a detrimen-
tal effect of PGRN in Ab deposition. In regard to tau pathology,
PGRN deficiency accelerates tau deposition and phosphorylation in
human tau-expressing mice (Hosokawa et al, 2015; Takahashi et al,
2017). Furthermore, an AD-associated GRN variant (rs5848), which
causes a decrease in PGRN levels in plasma and CSF (Rademakers
et al, 2008; Nicholson et al, 2014; Morenas-Rodrı´guez et al, 2015),
is associated with increased CSF T-tau levels in participants of the
ADNI study (Takahashi et al, 2017). Together, these results indicate
a protective role of PGRN against the development of tau pathology
and/or neurodegeneration.
PGRN is a 593 amino acid protein that contains seven and a half
tandem repeats forming the granulin domains (Bateman et al, 1990;
Bhandari et al, 1992). It is targeted through the secretory pathway
and secreted into the extracellular space. Secreted PGRN can be taken
up and targeted to endosomes/lysosomes (Hu et al, 2010; Zhou et al,
2015b). Proteolytic processing of full-length PGRN may generate indi-
vidual granulin peptides (Kleinberger et al, 2013; Holler et al, 2017).
Within the brain, PGRN is predominantly expressed by microglia
(Zhang et al, 2014; Lui et al, 2016; Chang et al, 2017), but some
expression is also observed in neurons. Moreover, PGRN is signifi-
cantly increased upon microglial activation (Daniel et al, 2000;
Naphade et al, 2010; Petkau et al, 2010; Philips et al, 2010; Klein-
berger et al, 2013; Suh et al, 2014). PGRN may be involved in the
modulation of neuroinflammation since PGRN-deficient mice exhibit
increased microglial activation and astrogliosis, as well as augmented
expression of proinflammatory cytokines (Yin et al, 2009, 2010;
Ahmed et al, 2010; Martens et al, 2012; Wils et al, 2012; Filiano
et al, 2013; Minami et al, 2014). Whereas deficiency in the triggering
receptor expressed on myeloid cells 2 (TREM2) locks microglia in a
homeostatic stage (Mazaheri et al, 2017), loss of PGRN leads to their
hyperactivation. Thus, deficiency of PGRN and TREM2 results in
opposite functional deficits (Go¨tzl et al, submitted).
Although genetic data and functional analyses in animal
models provide some evidence for an involvement of PGRN in
AD, no changes in CSF PGRN in AD compared to healthy
controls have been reported so far (Nicholson et al, 2014;
Ko¨rtve´lyessy et al, 2015; Morenas-Rodrı´guez et al, 2015; Wilke
et al, 2017). However, these studies focused primarily on AD
dementia and did not investigate the entire continuum of AD.
Given that CSF biomarkers, such as the shed ectodomain of the
triggering receptor expressed on myeloid cells 2 (sTREM2), show
dynamic changes throughout the course of AD (Sua´rez-Calvet
et al, 2016a,b), we aimed to cross-sectionally assess CSF PGRN
changes at different stages of the disease. To this end, we studied
a sample of persons at-risk for autosomal dominant AD (ADAD)
recruited within the Dominantly Inherited AD Network (DIAN;
http://dian.wustl.edu) (Bateman et al, 2012) and participants with
late-onset AD from the Alzheimer’s Disease Neuroimaging Initia-
tive (ADNI; http://adni.loni.usc.edu; Weiner et al, 2012). We
investigated whether CSF PGRN (i) increases in relation to the
clinical course of AD; (ii) is associated with cognitive impairment
and neuroimaging markers of neurodegeneration (fludeoxyglucose
positron emission tomography, FDG-PET and hippocampal
volume) in subjects with AD; and (iii) is associated with the
microglial-derived protein sTREM2 as well as biomarkers of
amyloid and tau pathology.
Results
CSF PGRN increases throughout the course of autosomal
dominant Alzheimer’s disease
Cross-sectionally, we assessed CSF PGRN in 215 participants
from the DIAN initiative, including 130 mutation carriers (MC)
and 85 non-carriers (NC; Table 1). All analyses described were
adjusted for gender, age and APOE e4 status, unless stated other-
wise.
The levels of CSF PGRN were significantly increased in
MC compared to NC (F1,210 = 17.6, P = 0.00004, Fig 1A,
Appendix Table S1). In contrast to CSF sTREM2 (Henjum et al,
2016; Heslegrave et al, 2016; Piccio et al, 2016; Sua´rez-Calvet et al,
2016a,b), CSF PGRN was not significantly associated with age,
neither in the entire sample (b = 0.118, P = 0.079), nor when strati-
fying by mutation status (for NC: b = 0.125, P = 0.283; for MC:
b = 0.131, P = 0.142, Fig 1B). Consistent with previous publications
(Nicholson et al, 2014; Morenas-Rodrı´guez et al, 2015), CSF PGRN
was higher in males than in females (F1,210 = 6.35, P = 0.012,
Fig 1C) and were not affected by APOE e4 status (F1,210 = 0.041,
P = 0.840). CSF PGRN did not differ between the three ADAD-asso-
ciated genes (PSEN1, PSEN2 and APP) among the MC participants
(F2,124 = 0.77, P = 0.464, Fig 1D).
We determined how CSF PGRN changes as a function of the esti-
mated years from expected symptom onset (EYO) in MC compared
to NC. Mean estimated levels of CSF PGRN at consecutive 5-year
interval EYO were computed by a linear regression model including
mutation status, EYO and gender as predictor variables (see Statisti-
cal analysis section). As described by Bateman et al (2012), we
tested first-, second- and third-order EYO terms (EYO, EYO2 and
EYO3, respectively) as well as their interaction with mutation status.
The first-order (i.e. linear) model best fitted the data
(Appendix Table S2). The interaction of EYO with mutation status
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was a significant predictor of CSF PGRN changes (P = 0.041), indi-
cating that the changes in CSF PGRN as a function of EYO differ
between MC and NC. We compared the estimated CSF PGRN at 5-
year EYO intervals by t-tests and observed that CSF PGRN started to
be significantly increased in MC compared to NC at EYO = 10
(Table 2, Fig 2A, Appendix Table S3).
Following the approach of previous DIAN studies (Bateman et al,
2012; Fagan et al, 2014; Sua´rez-Calvet et al, 2016a,b), we added
CSF PGRN in the temporal sequence of biomarker changes within
the course of ADAD (Fig 2B). Like CSF sTREM2, changes in CSF
PGRN occurred after alterations in markers for brain amyloidosis
and neuronal injury, as measured by CSF T-tau.
Next, we compared CSF PGRN in MC at different clinical stages
defined by the clinical dementia rating (CDR) score with that of the
NC. We hence compared four groups: NC, cognitively normal
(CDR = 0) MC, very mild dementia (CDR = 0.5) MC and mild-to-
severe dementia (CDR > 1) MC. Participants with a CDR ≥ 1 were
grouped together because of the low number of subjects in these
groups (Table 1). We conducted an analysis of covariance
(ANCOVA) adjusted for age, gender, APOE e4 status and education,
and we observed a significant difference between the four groups
(F3,207 = 5.77, P = 0.001). A least significant difference (LSD) pair-
wise post hoc comparisons revealed that all MC groups (CDR = 0:
M = 1002, SD = 186; CDR = 0.5: M = 1072, SD = 201; CDR ≥ 1:
M = 1065, SD = 214; pg/ml) had significantly higher CSF PGRN
than the NC (M = 927 pg/ml, SD = 174; P = 0.026, P = 0.0001 and
P = 0.018, respectively). No differences were found between the MC
groups at different clinical stages. Likewise, CSF PGRN levels were
not associated with Mini-Mental State Examination (MMSE;
P = 0.881) or CDR sum of boxes (CDR-SB; P = 0.812) among MC.
CSF PGRN increases throughout the course of late-onset
Alzheimer’s disease
To further validate our findings in subjects with late-onset
AD, we studied a total of 1,017 participants of the ADNI study
(demographics of the entire ADNI sample are summarized in
Appendix Table S4). In the entire sample, and consistent with the
Table 1. DIAN participants’ characteristics.
Autosomal dominant Alzheimer’s disease (DIAN study)
Non-carriers (NC) (n = 85) Mutation carriers (MC) (n = 130) P-value (group effect)
Age, years 40.0 (10.8) 39.9 (10.7) 0.955
Females, % 55.3 49.2 0.384
APOE e4 carriers, % 35.3 27.7 0.237
Participant EYO, y 6.81 (11.7) 6.68 (10.7) 0.931
Education level, y 14.8 (2.40) 13.7 (3.19) 0.005*
MMSE, scores 29.0 (1.26) 25.6 (6.16) < 0.0001*
CSF biomarkers, pg/mla
T-tau 60.1 (28.1) 130 (97.0) < 0.0001*
P-tau181P 30.5 (10.3) 69.8 (42.0) < 0.0001*
Ab1–42 425 (136) 322 (160) < 0.0001*
sTREM2 2,796 (1,305) 3,520 (1,640) 0.0007*
PGRNb 927 (174) 1,041 (199) 0.00004*
Cognitive status, %c
CDR = 0 96.5 43.1
CDR = 0.5 3.5 39.2
CDR = 1 0 11.5
CDR = 2–3 0 6.1
Family mutations, %d
PSEN1 58.8 77.7
PSEN2 14.1 8.5
APP 27.1 13.8
Ab1–42, amyloid-b 42; AD, Alzheimer disease; APOE, apolipoprotein E; APP, amyloid precursor protein; CSF, cerebrospinal fluid; EYO, estimated years from expected
symptom onset; MMSE, Mini-Mental State Examination; PSEN1, presenilin 1; PSEN2, presenilin 2; P-tau181P, tau phosphorylated at threonine 181; T-tau, total tau;
y, years.
Data are expressed as mean (M) and standard deviation (SD) or percentage (%), as appropriate. Pearson’s chi-square tests were used for the group comparisons
of categorical variables and two-sample independent t-tests to compare continuous variables.
*Significant differences. The P-values indicated in the last column refer to the group effects in these tests.
aCSF core biomarkers in DIAN were measured using the Luminex bead-based multiplexed xMAP technology (INNO-BIA AlzBio3, Innogenetics).
bCSF PGRN differences were assessed by a linear model adjusted for age, gender and APOE e4 status (see main text).
cCognitive status was defined by the clinical dementia rating (CDR) score (0, cognitively normal; 0.5, very mild; 1, mild; 2, moderate; 3, severe dementia).
dIn NC participants, the mutation present in their family is shown.
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Figure 1. Association of CSF PGRN with mutation status, age and gender.
A CSF PGRN is increased in mutation carriers (MC) compared to non-carriers (NC).
B CSF PGRN is not associated with age in either NC or MC.
C CSF PGRN is increased in males compared to females.
D CSF PGRN levels do not differ among MC participants carrying a PSEN1, PSEN2 or APP mutation.
Data information: The blue or red bars in (A), (C) and (D) represent the mean and the standard deviation (SD). Group comparisons were assessed by a linear model
adjusting by age, gender and APOE e4 status. The solid lines in (B) indicate the regression line for each of the groups and the 95% confidence interval (CI) calculated by a
linear model adjusting by gender and APOE e4 status. The standardized regression coefficients (b) and the P-values are also shown. In graph (B), the individual values are
not shown in order to protect participants’ confidentiality. All analysis and graphs are performed excluding 3 PGRN values outliers. Including the outliers in the analysis
rendered similar results (Appendix Table S1). APP, amyloid precursor protein; CSF, cerebrospinal fluid; ns, non-significant; PSEN1, presenilin 1; PSEN2, presenilin 2.
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findings in ADAD, CSF PGRN was higher in males than females
(F1,1013 = 26.4, P < 0.0001, Appendix Table S5). A trend towards
lower PGRN was observed in APOE e4 carriers (F1,1013 = 3.40,
P = 0.066), but was not associated with age (b = +0.049, P = 0.118).
In order to study the changes in CSF PGRN at different stages of
disease severity, we defined disease stage according to the recently
proposed biomarker-based A/T/N framework (Jack et al, 2016a)
in combination with the CDR score (Morris, 1993; Table 3). The A/
T/N classification is the basis of the 2018 National Institute on
Aging–Alzheimer’s Association (NIA-AA) Research Framework
(Jack et al, 2018) and defines three binary biomarker categories: (i)
aggregated Ab (A+/A), (ii) aggregated tau (T+/T) and (iii)
neurodegeneration or neuronal injury (N+/N). Herein, each of
these categories was defined using the AD CSF core biomarkers,
namely CSF Ab1–42 (A), P-tau181P (T) and T-tau (N). The aggregated
tau (T) and neurodegeneration (N) groups were merged together to
simplify the number of groups to compare (only 5.3% of the partici-
pants of the ADNI total sample displayed discrepancies between the
T and N biomarker groups; see Materials and Methods section for a
comprehensive description on the classification). We also classified
the participants based on their clinical status (C), as measured by
the well-established CDR global score (Morris, 1993), into cogni-
tively unimpaired (CDR = 0), very mild dementia (CDR = 0.5) and
mild dementia (CDR = 1). The combination of both the biomarker
Table 2. CSF PGRN estimates (pg/ml) in MCs and NCs as a function of EYO.
Estimated years from expected symptom onset (EYO)
25 20 15 10 5 0 +5 +10
Non-carriers 974 978 983 988 992 997 1,002 1,006
Mutation carriers 992 1,022 1,052 1,082 1,112 1,142 1,172 1,202
Difference 18 44 69 94 120 145 170 196
95% CI [104, 140] [64, 151] [27, 165] [4, 184] [29, 210] [48, 242] [62, 279] [72, 319]
P-value 0.768 0.423 0.159 0.040* 0.010* 0.004* 0.002* 0.002*
CI, confidence interval.
Mean estimated levels of CSF PGRN were obtained by a linear model including gender, mutation status, EYO and the interaction between mutation status and
EYO as covariates (see Statistical analysis section and Appendix Table S2). For each EYO, the group difference, 95% CI and the P-value for the two-sample
independent t-test are reported. Participants with EYO > +20 (1 NC and 2 MC) were excluded from the analysis. The same analysis including the PGRN outliers
and those participants with an EYO > +20 yielded identical results (Appendix Table S3). Differences are calculated from unrounded values.
*Significant difference.
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Figure 2. Changes in CSF PGRN as a function of EYO.
A CSF PGRN as a function of EYO in mutation carriers (MC, red) and non-carriers (NC, blue). The solid lines indicate the regression line for each of the groups and the
95% confidence interval (CI) calculated by a linear model adjusting by gender. The interaction term of mutation status and EYO is significant (P = 0.041), also when
including PGRN outliers and participants with EYO > +20 (P = 0.030). Individual data points are not displayed to prevent disclosure of mutation status.
B The graph depicts the standardized differences in CSF PGRN between MCs and NCs as a function of EYO, in the context of other biomarker and cognitive changes.
The curves were generated by the linear model that best fit each marker (see Statistical analysis section and Appendix Table S2). CSF PGRN is significantly increased
in MC compared to NC 10 years before the expected symptom onset (shadowed area) after brain amyloidosis and brain injury (as measured by CSF T-tau) have
started, and shortly before CSF sTREM2 starts to increase.
Data information: Ab1–42: amyloid-b 42; CSF, cerebrospinal fluid; MC, mutation carrier; MMSE, Mini-Mental State Examination; NC, non-carrier; T-tau, total tau.
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and the clinical classification rendered twelve different groups that
are summarized in Table 3. After classifying the participants of the
ADNI sample, we analysed the data following two approaches. In a
first approach, we attempted to model disease stages within the
Alzheimer’s continuum as a combination of biomarkers and clinical
symptoms similar to what was proposed by the previous 2011 NIA-
AA diagnostic criteria (Albert et al, 2011; McKhann et al, 2011;
Sperling et al, 2011), and it was done in order to render the disease
staging in late-onset AD more comparable to that in ADAD defined
by EYO. Second, in an exploratory approach, we compared PGRN
levels between the different A/T/N categories within each clinical
stage.
Thus, we first asked whether CSF PGRN increases in relation to
the biomarker-defined clinical stages, and hence parallels PGRN
changes as a function of EYO in ADAD. For this purpose, we
compared the “healthy control” group (highlighted in light grey in
Table 3) with those groups that belong to the Alzheimer’s contin-
uum (highlighted in middle grey in Table 3). We hence compared
five groups in this first analysis, namely (i) “healthy controls”, (ii)
“Preclinical AD A+/TN” (iii) “Preclinical AD A+/TN+” (iv) “AD
CDR = 0.5” and (v) “AD CDR = 1”.
The demographics and clinical features of these groups are
summarized in Table 4. We conducted an ANCOVA controlling for
age, gender and APOE e4 status, and we found that CSF PGRN
significantly differed between groups (F4,594 = 7.32, P < 0.0001).
Bonferroni corrected pair-wise post hoc comparisons indicated that
CSF PGRN was significantly higher in the “AD CDR = 1” group
compared to the “healthy controls” (P = 0.006) and “Preclinical AD
A+/TN” (P < 0.0001) groups (Fig 3 and Table 4). Interestingly,
the “Preclinical AD A+/TN” group had significantly lower CSF
PGRN than the rest of the Alzheimer’s continuum groups (Fig 3 and
Table 4) but not to “healthy controls”. No other group differences
were found.
Given that GRN rs5848 is a well-known modifier of PGRN levels
(Rademakers et al, 2008; Nicholson et al, 2014; Morenas-Rodrı´guez
et al, 2015), we repeated the same analysis but also accounting for
the rs5848 genotype, which was available for 58.5% of the cases
(see Table 4). CSF PGRN still significantly differed between groups
(F4,342 = 5.66, P = 0.0002), where significant differences were
observed when “AD CDR = 1” was compared to “healthy controls”
(P = 0.030) and “Preclinical AD A+/TN” (P = 0.0001) groups in
Bonferroni corrected pair-wise post hoc comparisons. Similarly, CSF
PGRN remained lower in “Preclinical AD A+/TN” compared to
“AD CDR = 0.5” (P = 0.002) and “AD CDR = 1” (P = 0.0001)
groups and a tendency existed when compared to “Preclinical AD
A+/TN+” (P = 0.082). Consistent with previous reports (Rademak-
ers et al, 2008; Nicholson et al, 2014; Morenas-Rodrı´guez et al,
2015), there was a significant effect of the GRN rs5848 genotype on
CSF PGRN levels (F2,342 = 20.6, P < 0.0001), such that the CSF
PGRN mean level of the GRN rs5848 TT carriers (M = 1348 pg/ml,
SD = 330) was significantly lower than that of the rs5848 CT carri-
ers (M = 1524 pg/ml, SD = 277, P = 0.0001) and rs5848 CC carriers
(M = 1659 pg/ml, SD = 379, P < 0.0001) groups (Bonferroni
corrected pair-wise post hoc comparisons). Together, the CSF PGRN
changes across biomarker-defined clinical stages are consistent with
the increase we found in ADAD throughout EYO.
To further confirm that CSF PGRN changes across the disease
course, we also tested whether CSF PGRN levels are associated with
cognitive and functional scores in those participants that fall in the
Alzheimer’s continuum category (Table 5; Fig 4). Our primary
cognitive measures were the composite scores ADNI-Mem (Fig 4A),
for memory performance, and ADNI-EF (Fig 4B), for executive func-
tion, since they have been previously validated in the ADNI study,
are robust and have external validity (Crane et al, 2012; Gibbons
et al, 2012; Habeck et al, 2012). We computed three linear regres-
sion models, including as main predictors: unadjusted (Model 1);
adjusted for age, gender, APOE e4 status and education (Model 2);
and additionally adjusted for CSF Ab1–42 and CSF T-tau (Model 3,
Table 5). Higher CSF PGRN was associated with lower memory
performance as measured by ADNI-Mem (b = 0.145, P = 0.002)
and executive function as assessed by ADNI-EF (b = 0.145,
P = 0.002) in an unadjusted model (Model 1, Table 5 and
Appendix Table S6). These associations remained significant after
adjustment for age, gender, APOE e4 status and education (Model 2,
ADNI-Mem: b = 0.140, P = 0.002, Fig 4A; ADNI-EF: b = 0.150,
P = 0.0008, Fig 4B; Table 5 and Appendix Table S6). We also stud-
ied ADAS-Cog 11, ADAS-Cog 13, MMSE and CDR-SB as secondary
cognitive measures, and the results were similar (Fig 4C–F, Table 5
and Appendix Table S6). The associations remain significant after
accounting for Ab1–42 and T-tau (Model 3) for ADNI-EF, ADAS-Cog
11 and ADAS-Cog 13, and a tendency existed for ADNI-Mem and
MMSE (Table 5, Appendix Table S6), indicating that the association
between CSF PGRN and cognitive scores is, at least in part, not
dependent on the AD CSF core biomarkers.
We also tested whether CSF PGRN is associated with neuroimag-
ing biomarkers of neurodegeneration typically affected in AD,
namely temporo-parietal FDG-PET uptake and total hippocampal
volume, in the Alzheimer’s continuum category (Fig 5). In a linear
Table 3. Classification of ADNI participants based on their biomarker
profile and clinical stage.
A, amyloid-b biomarker status; AD, Alzheimer’s disease; CDR, clinical
dementia rating; N, neurodegeneration biomarker status; T, tau pathology
biomarker status.
ADNI participants were classified based on their CSF biomarker profile and
their clinical stage, which yielded 12 different categories. Columns depict the
clinical stage (C) as defined by the clinical dementia rating (CDR) scale. Rows
depict the biomarker profiles. Each of the three biomarker groups (A/T/N) was
binarized into positive or negative (+/). T and N were merged to simplify
the classification: TN indicates that both T and N biomarkers are normal,
and TN+ indicates that T and/or N biomarkers are abnormal.
The grey highlighting indicates the grouping used for comparisons in the
main text. Light grey highlights the healthy controls (n = 128), middle grey
the groups included in the Alzheimer’s continuum (n = 474) and dark grey
the suspected non-Alzheimer’s pathophysiology (SNAP) group (n = 182). Bold
text indicates the groups analysed in the main analysis, namely “healthy
controls”, “Preclinical AD A+/TN”, “Preclinical AD A+/TN+”, “AD CDR = 0.5”
and “AD CDR = 1”.
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regression analysis adjusted for age, gender, APOE e4 status and
education, higher CSF PGRN was associated with lower temporo-
parietal FDG-PET uptake (b = 0.133, P = 0.010) (Fig 5A), but not
total hippocampal volume (b = 0.063, P = 0.151, Fig 5B).
In the second approach, we examined CSF PGRN between
biomarker profile [as defined by the A/T/N classification (Jack et al,
2016a)] within each clinical stage (Fig EV1A). Unlike the former
analysis of the Alzheimer’s continuum, this is an unbiased compar-
ison that does not assume any particular sequence of biomarkers in
the course of the disease. Appendix Table S4 displays a summary of
the demographics of the entire ADNI sample, analysed here. As
expected, the CDR = 1 clinical stage had some biomarker profiles
with low number of subjects that preclude any comparisons but are
shown in Fig EV1A for the sake of completeness. Following this
approach, we found that the “ATN+” biomarker profiles (i.e.
SNAP) had the highest CSF PGRN, which was significantly higher
than the rest of the biomarker profiles within the same clinical stage
(Fig EV1A). On the contrary, the “A+TN” biomarker profiles had
the lowest CSF PGRN. We next grouped the subjects that fall into
each of the biomarker category of “suspected non-Alzheimer’s
pathophysiology” (SNAP; Table 3, highlighted in dark grey) (Jack
et al, 2012, 2016b; Caroli et al, 2015; Dani et al, 2017) and we
compared them to the healthy controls and the Alzheimer’s contin-
uum category as a whole. CSF PGRN significantly differ between
categories (F2,778 = 24.7, P < 0.0001, Fig EV1B), and Bonferroni
corrected pair-wise post hoc tests showed that CSF PGRN was signif-
icantly higher in the SNAP category compared to the healthy
controls (P < 0.0001) and Alzheimer’s continuum categories
(P < 0.0001). Finally, we also tested the association between CSF
PGRN and cognitive function and neuroimaging biomarkers within
the SNAP category, with the same linear regression models we
applied in the analysis focused on the Alzheimer’s continuum cate-
gory. Strikingly, and in contrast with the results in the Alzheimer’s
continuum, CSF PGRN was not associated with cognitive decline in
the SNAP group in any of the models tested (Appendix Table S7). In
line with this finding, CSF PGRN was also not associated with
temporo-parietal FDG-PET uptake in the SNAP group (b = +0.102,
P = 0.203). These results suggest that, despite the fact that CSF
PGRN is increased in SNAP, it selectively associates with disease
severity in AD.
Table 4. ADNI participants’ characteristics for the control and Alzheimer’s continuum groups in ADNI.
Healthy
controls
(n = 128)
Alzheimer’s continuum (n = 474)
P-value (group
effect)
Preclinical
AD A+/TN
(n = 56)
Preclinical AD
A+/TN+ (n = 48)
AD CDR = 0.5
(n = 289)
AD CDR = 1
(n = 81)
Age, years 72.5 (5.37) 73.2 (5.96) 76.5 (5.37) 73.3 (7.05) 73.8 (9.27) 0.017*
Female, % 48.4 46.4 52.1 42.6 50.6 0.542
APOE e4 carriers, % 14.8 39.3 58.3 76.5 74.1 < 0.0001*
GRN rs5848 TT carriers, %a 5.20 13.2 6.90 13.6 14.8 0.472
Education, y 16.3 (2.79) 16.5 (2.74) 16.5 (2.47) 15.9 (2.87) 15.1 (2.78) 0.010*
Cognitive tests, scores
ADNI-Mem 1.14 (0.59) 1.04 (0.61) 0.86 (0.56) 0.28 (0.64) 1.02 (0.46) < 0.0001*
ADNI-EF 0.94 (0.75) 0.74 (0.70) 0.40 (0.61) 0.12 (0.79) 1.07 (0.78) < 0.0001*
ADAS-Cog11 5.96 (3.12) 5.85 (3.06) 6.54 (3.01) 13.2 (5.34) 23.2 (6.98) < 0.0001*
ADAS-Cog13 8.94 (4.57) 9.27 (4.51) 10.2 (4.45) 21.2 (7.38) 34.6 (7.95) < 0.0001*
MMSE 29.1 (1.12) 28.9 (1.23) 29.0 (1.20) 26.3 (2.39) 22.7 (2.06) < 0.0001*
CDR-SB 0.016 (0.09) 0.054 (0.16) 0.073 (0.21) 2.09 (1.09) 5.62 (1.17) < 0.0001*
CSF biomarkers, pg/mlb
T-tau 184 (31.8) 166 (41) 329 (77.5) 382 (135) 395 (137) < 0.0001*
P-tau181P 16.3 (2.87) 15.4 (4.09) 33.0 (8.93) 39.1 (14.5) 39.4 (15.1) < 0.0001*
Ab1–42 1,455 (227) 724 (193) 712 (173) 636 (167) 575 (159) < 0.0001*
PGRNc 1,502 (279) 1,394 (365) 1,569 (305) 1,541 (343) 1,649 (375) < 0.0001*
A, amyloid-b biomarker status; Ab1–42, amyloid-b 42; AD, Alzheimer disease; APOE, apolipoprotein E; ADAS-Cog, Alzheimer’s disease Assessment Scale—cognitive
subscale; ADNI-Mem, ADNI memory composite score; ADNI-EF, ADNI executive function composite score; CDR, clinical dementia rating; CDR-SB, clinical dementia
rating sum of boxes; CSF, cerebrospinal fluid; MMSE, Mini-Mental State Examination; N, neurodegeneration biomarker status; P-tau181P, tau phosphorylated at
threonine 181; T, tau pathology biomarker status; T-tau, total tau; y, years.
Data are expressed as mean (M) and standard deviation (SD) or percentage (%), as appropriate. Pearson’s chi-square tests were used for the group comparisons
of categorical variables and one-way ANOVA to compare continuous variables.
*Significant differences. The P-values indicated in the last column refer to the group effects in these tests.
aGRN rs5848 genotype was available in 77 “healthy controls” (60%), 38 “Preclinical AD A+/TN” (68%), 29 “Preclinical AD A+/TN+” (60%), 154 “AD CDR = 0.5”
(53%) and 54 “AD CDR = 1” (67%).
bThe CSF core biomarker measurements were performed using the electrochemiluminescence immunoassays, total-tau CSF, phospho-tau(181P) CSF and Elecsys
b-amyloid(1–42) CSF. The Elecsys b-amyloid(1–42) assay has an upper technical limit of 1700 pg/ml; the values above this limit were truncated to this value.
cCSF PGRN levels were log-transformed and assessed by a linear model adjusted for age, gender and APOE e4 status (see main text).
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CSF PGRN is not a clinical diagnostic biomarker for AD
We assessed the diagnostic accuracy of CSF PGRN to discriminate
between AD and controls. To this regard, a receiver operating
characteristic (ROC) curve analysis was undertaken (Fig EV2). The
area under the curve (AUC) was 0.655 (95% CI 0.581–0.729,
P = 0.0001, Fig EV2A) for discriminating ADAD mutation carriers
from non-carriers of the DIAN study, and 0.607 (95% CI 0.528–
0.686, P = 0.009, Fig EV2B) for discriminating late-onset AD
CDR = 1 from healthy controls. Although the significant P-values
denote that the AUC of CSF PGRN is significantly different from the
area under the diagonal, which corresponds to a random perfor-
mance of a test, these are low AUC that indicate a poor accuracy to
discriminate between AD and controls. Together with the fact that
CSF PGRN considerably overlaps between groups, these results
show that, consistent with previous data (Nicholson et al, 2014;
Ko¨rtve´lyessy et al, 2015; Morenas-Rodrı´guez et al, 2015; Wilke
et al, 2017), CSF PGRN is not useful as a diagnostic marker in AD.
CSF PGRN is associated with CSF sTREM2 and markers of
neurodegeneration in both autosomal dominant and late-onset
Alzheimer’s disease
We and others previously described an increase in the microglial-
derived protein sTREM2 in the CSF of both ADAD and late-onset AD
patients (Heslegrave et al, 2016; Piccio et al, 2016; Sua´rez-Calvet
et al, 2016a,b). Since CSF PGRN also gradually increases during the
course of the disease and it is mainly produced by activated micro-
glia (Daniel et al, 2000; Naphade et al, 2010; Petkau et al, 2010;
Philips et al, 2010; Kleinberger et al, 2013; Suh et al, 2014), we
investigated whether these two proteins are associated (Figs 6A and
B, and 7A–C). In a linear regression model, we found that CSF
PGRN and CSF sTREM2 were significantly associated in ADAD
mutation carriers of the DIAN study (b = +0.514, P < 0.0001,
Fig 6B). Similarly, CSF PGRN and sTREM2 were also significantly
associated in individuals of the Alzheimer’s continuum (b = +0.344,
P < 0.0001, Fig 7B) and the SNAP category (b = +0.296, P < 0.0001,
Fig 7C) of the ADNI study. Importantly, these associations only
occurred in AD and SNAP since no association was found in the NC
of the DIAN study (b = +0.094, P = 0.424, Fig 6A) and in the
healthy controls of the ADNI study (b = +0.106, P = 0.246, Fig 7A).
Together, these results suggest that, whenever there is neurodegen-
eration (triggered by amyloidosis or other causes), there is a concur-
rent release of the microglial proteins PGRN and sTREM2 into the
CSF.
We also tested the associations between CSF PGRN and each of
the core CSF biomarkers of AD (T-tau, P-tau181P and Ab1–42) in
linear regression models for both ADAD (DIAN) and late-onset AD
(ADNI) (Figs 6C–H and 7D–L; Appendix Table S8 summarizes the
results including biomarker outliers). The results paralleled those
we previously found for CSF sTREM2 (Sua´rez-Calvet et al, 2016a,
b). CSF PGRN was associated with CSF T-tau and CSF P-tau181P,
markers of neurodegeneration and neurofibrillary tangle degenera-
tion, respectively, in both ADAD mutations carriers (T-tau:
b = +0.258 P = 0.008; P-tau181P: b = +0.191, P = 0.041; Fig 6D and
F) and NC (T-tau: b = +0.240 P = 0.032; P-tau181P: b = +0.290,
P = 0.008, Fig 6C and E). Interestingly, this association was only
present in the ADNI subjects of the Alzheimer’s continuum (T-tau:
b = +0.295 P < 0.0001; P-tau181P: b = +0.280, P < 0.0001; Fig 7E
and H), but not in healthy controls (T-tau: b = +0.157 P = 0.087;
P-tau181P: b = +0.118, P = 0.195; Fig 7D and G) or SNAP subjects
(T-tau: b = +0.043 P = 0.564; P-tau181P: b = +0.104, P = 0.172;
Fig 7F and I). These findings are consistent with the fact that CSF
PGRN is only associated with cognitive impairment in the Alzhei-
mer’s continuum category but not in SNAP and support the idea that
CSF PGRN parallels the burden of the disease specifically in AD.
In contrast, we did not observe an association between CSF
PGRN and Ab1–42 in either NC or MC of the DIAN sample (Fig 6G
and H) and only a weak association was found in the Alzheimer’s
continuum and SNAP participants of the ADNI sample (Fig 7J–L).
Discussion
In this cross-sectional study, we found that CSF PGRN increases
throughout the course of AD, both in ADAD and in late-onset AD.
Furthermore, CSF PGRN is associated with the microglial-derived
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Figure 3. CSF PGRN levels across the Alzheimer’s continuum.
Scatter plot representing the levels of CSF PGRN in healthy controls (depicted in
blue) and the different stages of the Alzheimer’s continuum (depicted in red). The
blue and the red bars represent the mean and the standard deviation (SD). The
analysis and graphs were performed excluding CSF PGRN outliers (1 “healthy
control”, 1 “Preclinical AD A+/TN”, 4 “AD CDR = 0.5” and 1 “AD CDR = 1”).
Including them yielded a similar result, and CSF PGRN was still significantly
higher in the “AD CDR = 1” group compared to the “healthy controls” (P = 0.001)
and “Preclinical AD A+/TN” (P = 0.0001) groups. P-values were assessed by a
one-way analysis of covariance adjusted for age, gender and APOE e4, followed by
Bonferroni corrected pair-wise post hoc comparisons. A: amyloid-b biomarker
status; AD: Alzheimer’s disease; CDR: clinical dementia rating; CSF, cerebrospinal
fluid; N, neurodegeneration biomarker status; T: tau pathology biomarker status.
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Table 5. Associations of CSF PGRN with cognitive measures in the Alzheimer’s continuum category (ADNI sample).
Model 1 (unadjusted)
Model 2 (adjusted for age, gender,
APOE e4 and education)
Model 3 (also adjusted
for Ab1–42 and T-tau)
b P b P b P
ADNI-Mem 0.145 0.002* 0.140 0.002* 0.080 0.064
ADNI-EF 0.145 0.002* 0.150 0.0008* 0.116 0.001*
ADAS-Cog 11 +0.138 0.003* +0.135 0.003* +0.095 0.036*
ADAS-Cog 13 +0.149 0.001* +0.148 0.001* +0.108 0.016*
MMSE 0.126 0.006* 0.126 0.006* 0.087 0.052
CDR-SB +0.174 0.011* +0.125 0.007* +0.070 0.119
Ab1–42, amyloid-b 42; ADAS-Cog, Alzheimer’s disease Assessment Scale—cognitive subscale; ADNI-Mem, ADNI memory composite score; ADNI-EF, ADNI executive
function composite score; CDR-SB, clinical dementia rating sum of boxes; MMSE, Mini-Mental State Examination; T-tau, total tau.
Associations between CSF PGRN and cognitive measures were studied only in the participants of the Alzheimer’s continuum (n = 474) and were assessed by three
different linear regression models. The standardized regression coefficients (b) and the P-values are shown.
Note that higher levels of CSF PGRN are associated with worse cognitive performance in all tests investigated even when age, gender APOE e4 status and
education (Model 2) are accounted. The associations still remain after adding Ab1–42 and T-tau as added in the model (Model 3) in all tests except in ADNI-Mem,
MMSE and CDR-SB.
The analysis was performed excluding CSF PGRN outliers. The same analysis including these outliers yielded similar results (Appendix Table S6). There were two
subjects without ADAS-Cog11 score and six subjects without ADAS-Cog13 scores.
*Significant differences.
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Figure 4. CSF PGRN as a function of cognitive function.
Scatter plots representing the association of CSF PGRNwith different cognitive tests. Only the subjects of the Alzheimer’s continuum group (n = 474) were included. In all tests
studied, higher levels of CSF PGRN were associated with worse cognitive performance (namely lower scores in ADNI-Mem, ADNI-EF and MMSE and higher scores in ADAS-
Cog11, ADAS-Cog13 and CDR-SB). The analysis and the graphs are excluding PGRN outliers; including them rendered similar results (Appendix Table S6). Each point depicts the
value of CSF PGRN and the corresponding cognitive test score of a participant. The solid lines indicate the regression line and the 95% confidence interval (CI) calculated by a
linear model (Model 1, unadjusted). Table 5 shows the standardized regression coefficients (b) and the P-values calculated by different models. ADAS-Cog, Alzheimer’s disease
Assessment Scale—cognitive subscale; ADNI-Mem: ADNI memory composite score; ADNI-EF: ADNI executive function composite score; CDR-SB: clinical dementia rating sum
of boxes; MMSE, Mini-Mental State Examination.
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protein sTREM2 and with markers of neuronal injury (T-tau) and
neurofibrillary tangle degeneration (P-tau181P). Given that both
PGRN and sTREM2 are predominantly expressed in microglia within
the brain, our findings provide further evidence for a crucial role of
microglia in modulation of onset and progression of AD. While CSF
PGRN cannot serve as a diagnostic marker in AD, PGRN may serve
as microglial activity marker that, together with sTREM2, could
allow tracking microglial phenotypes not only during the course of
the disease but also during therapeutic interventions. Furthermore,
since loss of TREM2 and PGRN results in opposite phenotypes
(Go¨tzl et al, submitted), our findings may also allow to track dif-
ferent activation stages of microglia upon TREM2 or PGRN loss of
function. Our study also further reinforces that PGRN is relevant not
only for FTD but also for AD.
Although the results in ADAD and late-onset AD consistently
show a continuous increase in CSF PGRN while disease progresses,
differences between ADAD and late-onset AD were observed. While
in ADAD CSF PGRN increased early in the disease (10 years before
the expected symptom onset), in late-onset AD, the CSF PGRN levels
did not reach a significant increase compared to healthy controls
until the mild dementia stage (CDR = 1). Importantly, however, all
late-onset AD groups in the Alzheimer’s continuum had increased
CSF PGRN levels compared with the earliest stage of AD, the
“Preclinical AD A+TN” group, which had the lowest CSF PGRN
levels. This means that once neurodegeneration and neurofibrillary
tangle degeneration have started (as expressed by the N and T posi-
tivity, respectively), CSF PGRN increases. This parallels what occurs
in ADAD, where CSF T-tau (and hence, probably neurodegeneration
as well) significantly increases 15 years before the symptom onset
(Bateman et al, 2012; Fagan et al, 2014; Sua´rez-Calvet et al, 2016a,
b) and this is followed by the later increase in CSF PGRN
(EYO = 10, as shown in the present study) and CSF sTREM2
(EYO = 5; Sua´rez-Calvet et al, 2016a,b). Our conclusion is
further supported by the fact that CSF PGRN is associated with CSF
T-tau, P-tau181P, cognitive impairment and temporo-parietal FDG
specifically in late-onset AD, but not in SNAP. This may indicate
that, although CSF PGRN production may be increased whenever
there is neuronal injury, CSF PGRN is specifically coupled to the
progression of neurodegeneration in AD. In contrast, CSF PGRN was
not associated with hippocampal volume, which may suggest a
more complex link between inflammatory-related biomarkers such
as CSF PGRN and structural imaging. In fact, CSF sTREM2 was
found to be positively associated with grey matter volume in mild
cognitive impairment due to AD, despite the fact that CSF sTREM2
increases throughout the early stages of the disease, which was
attributed to a possible brain swelling (Gispert et al, 2016). CSF
PGRN was not either associated with cognitive measurements in
ADAD, despite its increase throughout EYO and its clear association
with CSF T-tau and P-tau181P. This may suggest that in ADAD, CSF
PGRN increases early in the disease but remains stable throughout
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Figure 5. CSF PGRN as a function of neuroimaging biomarkers.
A, B Scatter plots representing the association of CSF PGRN with temporo-parietal FDG-PET uptake (A) and total hippocampal volume (B) within the subjects of the
Alzheimer’s continuum group (n = 474). Each point depicts the value of CSF PGRN and the corresponding neuroimaging biomarker of a participant. The solid lines
indicate the regression line and the 95% confidence interval (CI). The regression coefficients (b) and the P-values calculated by a linear model adjusted for age,
gender, APOE e4 and education. FDG-PET: fludeoxyglucose positron emission tomography; SUVR: standardized uptake value ratio.
▸Figure 6. Association of CSF PGRN with AD core CSF biomarkers in ADAD (DIAN).A–H Scatter plots representing the associations of CSF PGRN with CSF sTREM2 and each of the AD CSF core biomarkers (T-tau, P-tau181P and Ab142) in non-carriers
(NC, blue; A, C, E and G) and in mutation carriers (MC, red; B, D, F and H). Each point depicts the value of CSF PGRN and the corresponding biomarker of a subject
and the solid lines indicate the regression line and the 95% confidence interval (CI) for each of the groups. The standardized regression coefficients (b) and the P-
values are shown and were computed using a linear model adjusting for age, gender and APOE e4. The sample contained some outliers (defined as 3 SDs below or
above the group mean) of the CSF core markers of AD. The results shown in the figure are excluding these outliers. We also performed the analysis including these
outliers which yielded similar results (Appendix Table S8). Ab1–42: amyloid-b 42; T-tau: total tau; P-tau: tau phosphorylated at threonine 181.
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the later clinical progression. In ADAD, the causative PSEN1, PSEN2
and APP mutations are such strong driving forces of disease pathol-
ogy that other factors, such as PGRN, may be less associated with
cognition.
In contrast to our findings, previous studies did not detect an
increase of CSF PGRN in AD (Nicholson et al, 2014; Ko¨rtve´lyessy
et al, 2015; Morenas-Rodrı´guez et al, 2015; Wilke et al, 2017). This
is likely due to the fact that DIAN and ADNI provide a number of
samples and an exhaustive clinical data that is unrivalled by any
other cohort. In DIAN, we can compare mutation carriers, which
are destined to develop AD, with the best controls possible, that is,
their non-carriers’ siblings. A further advantage of studying ADAD
is the use of the concept of estimated years from expected symptom
onset (EYO) as a proxy of disease evolution to predict a temporal
progression of CSF PGRN, despite the fact that this is a cross-
sectional study. This approach has been well validated by studies of
the DIAN consortium that have shown that there is a high correla-
tion between the parental age of onset and the mean age at onset of
the affected family members (from which EYO is derived) and the
actual age of onset (Ryman et al, 2014). Finally, in our study we
applied an unbiased approach to classify the participants of ADNI,
based on biomarker profile (A/T/N) and cognition (C), which made
us independent of different diagnostic schemes in different centres
(Jack et al, 2016a). That allowed us to study those groups that are
included in the Alzheimer’s continuum, from preclinical to mild
dementia stages of the disease, and compare them with the evolu-
tion of the disease in ADAD as defined by EYO.
The precise mechanism underlying the increase in CSF PGRN
during AD has yet to be determined. Since PGRN is highly
increased upon activation of microglia (Petkau et al, 2010), we
speculate that increased CSF PGRN reflects elevated microglial
function. It is well established that activation of microglia occurs
in AD (Lyman et al, 2014; Heneka et al, 2015) and, in fact, we and
others have previously shown that CSF sTREM2 also increases
throughout the evolution of the disease (Heslegrave et al, 2016;
Piccio et al, 2016; Sua´rez-Calvet et al, 2016a,b). A remarkable
finding of this study is that higher CSF PGRN levels are associated
with higher CSF sTREM2 levels exclusively when disease occurs
(either in ADAD MC, late-onset AD or in SNAP) but not in
controls. This may indicate that these two proteins are released by
microglia adopting a disease-associated signature (Keren-Shaul et al,
2017; Krasemann et al, 2017). However, it is also possible that
these two proteins reflect different populations of microglia co-
existing in the disease and may even have opposing effects on
disease. While lack of TREM2 locks microglia in a homeostatic state
(Mazaheri et al, 2017), lack of PGRN locks microglia in a hyperac-
tive state (Go¨tzl et al, submitted). Whether these responses are
beneficial or detrimental in the disease may depend on the stage of
the disease and needs to be addressed in longitudinal studies. The
fact that CSF PGRN is associated with the microglial-derived protein
CSF sTREM2 and both are associated with markers of neuronal
injury and neurofibrillary tangle degeneration suggests that elevated
levels of CSF PGRN and CSF sTREM2 early during the disease
reflect a microglial response to neuronal injury. In line with this,
recent studies demonstrated that disease-associated TREM2 variants
cause a loss of function suggesting that TREM2 is protective (Klein-
berger et al, 2014, 2017; Wang et al, 2015; Song et al, 2018). Simi-
larly, haploinsufficiency of PGRN causes FTD (Baker et al, 2006;
Cruts et al, 2006), and a complete loss of PGRN results in a lysoso-
mal storage disorder with severe neurodegeneration (Smith et al,
2012; Go¨tzl et al, 2014). Therefore, TREM2 and PGRN may have a
protective function at least early during the disease. TREM2 clearly
has a cell-autonomous function mediated via DAP12 signalling
within microglia (Colonna & Wang, 2016). However, sTREM2,
which is released on the plasma membrane, may also have non-
cell-autonomous functions. Similarly, PGRN is either targeted
directly from the trans-Golgi to lysosomes (where it then may have
cell-autonomous functions) or released via the secretory pathway
(Go¨tzl et al, 2016). In that case PGRN, like sTREM2, may have
intrinsic functions within microglia, but both proteins may be able
to affect cellular functions in non-microglial cells as well.
Finally, it is important to note that CSF PGRN has no utility as a
diagnostic marker in AD since the values overlap considerably
between groups. This study has to be interpreted from the perspec-
tive of the pathophysiological importance of PGRN in AD, and not as
the evaluation of a putative diagnostic biomarker. Taken together,
PGRN and sTREM2 may both be increased early in the disease upon
an initial response of microglia to first neuronal injury. Their CSF
levels may therefore allow conclusions about the functional status of
microglia. This is also of specific value for the investigation of novel
strategies aiming to modulate microglial activity.
Materials and Methods
DIAN participants and study design
The DIAN study is a multicentre study initiated in 2008 that aims to
develop a registry of families with known ADAD mutations (namely
PSEN1, PSEN2 or APP) and investigate the pathophysiological
changes that occur in the different stages of AD (Bateman et al,
2012; Morris et al, 2012; Sua´rez-Calvet et al, 2016a,b). We
measured CSF PGRN from a total of 218 participants, 131 mutation
carriers (MC) and 87 non-carriers (NC). All DIAN participants
underwent a comprehensive clinical and neuropsychological evalua-
tion (Bateman et al, 2012; Storandt et al, 2014). CSF collection
◀ Figure 7. Association of CSF PGRN with AD core CSF biomarkers in late-onset AD (ADNI).A–L Scatter plots representing the associations of CSF PGRN with CSF sTREM2 and each of the AD CSF core biomarkers (T-tau, P-tau181P and Ab1–42) in healthy controls
(blue; A, D, G and J), Alzheimer’s continuum (red; B, E, H and K) and “suspected non-Alzheimer’s pathophysiology (SNAP)” groups (green; C, F, I and L). Each point
depicts the value of CSF PGRN and the corresponding biomarker of a subject, and the solid lines indicate the regression line and the 95% confidence interval (CI) for
each of the groups. The standardized regression coefficients (b) and the P-values are shown and were computed using a linear model adjusting for age, gender and
APOE e4. The sample contained some outliers (defined as 3 SDs below or above the group mean) of the CSF core markers of AD, and the analysis including these
outliers yielded similar results (Appendix Table S8). The Ab1–42 values used for the association test are those based on an extrapolation curve since the upper
technical limit is 1,700 pg/ml. We also tested the associations with Ab1–42 values truncated at the upper technical limit and the result was similar. Ab1–42: amyloid-
b 42; T-tau: total tau; P-tau: tau phosphorylated at threonine 181; SNAP: suspected non-Alzheimer’s pathophysiology.
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follows standard procedures (Fagan et al, 2014; Monserrate et al,
2015), and the measurements of T-tau, P-tau181P and CSF Ab1–42
were performed by the Luminex bead-based multiplexed xMAP
technology (INNO-BIA AlzBio3, Innogenetics; Fagan et al, 2014).
The estimated years from expected symptom onset (EYO) is calcu-
lated as the difference between the participant’s age at evaluation
and the mean age at onset of all other affected family members
(Bateman et al, 2012; Ryman et al, 2014).
ADNI participants and study design
The ADNI project (http://adni.loni.usc.edu) is a multicentre longitudi-
nal study led by Principal Investigator Michael Weiner and with the
main goal to develop and validate biomarkers for subject selection
and as surrogate outcome measures in late-onset AD (Weiner et al,
2017). Inclusion and exclusion criteria for the ADNI study were previ-
ously described comprehensively (Petersen et al, 2010).
For the present study, we measured CSF PGRN in a cross-
sectional sample of the ADNI project consisting of a total of 1,028
individuals. The criteria to select the participants are described in
the Appendix Table S9. The CSF PGRN measurements were
uploaded to the ADNI database (http://adni.loni.usc.edu) on 16/03/
2018, and all the data from ADNI used in this study were down-
loaded on 21/03/2018.
The CSF core biomarker measurements in ADNI were performed
using the electrochemiluminescence immunoassays Elecsys total-
tau CSF, phosphor-tau(181P) CSF and b-amyloid (1–42) CSF on a
fully automated Elecsys cobas e 601 instrument (Roche) and a single
lot of reagents for each of the three measured biomarkers (provided
in UPENNBIOMK9.csv file available at http://adni.loni.usc.edu).
These immunoassays are for investigational use only. They are
currently under development by Roche Diagnostics and not
commercially available yet. The Elecsys b-amyloid (1–42) CSF assay
measuring range beyond the upper technical limit has not been
formally established. Therefore, use of values above the upper tech-
nical limit, which are provided based on an extrapolation of the cali-
bration curve, is restricted to exploratory research purposes and is
excluded for clinical decision making or for the derivation of medi-
cal decision points. The analyte measuring ranges (lower technical
limit to upper technical limit) of these assays are the following: 80–
1,300 pg/ml for total-tau CSF, 8–120 pg/ml for phosphor-tau(181P)
and 200–1,700 pg/ml for Elecsys b-amyloid (1–42) CSF immunoas-
says. There were 160 values of Ab1–42 that were above the upper
technical limit and were truncated to 1,700 pg/ml. There were no
samples with T-tau or P-tau181P values above its respective upper
technical limit of quantification. For Ab1–42, exploratory measure-
ments are available based on the extrapolation of the calibration
curve. The associations of the CSF biomarkers described in the text
are using these extrapolated values. The analysis using the Ab1–42
truncated values and those using the extrapolated measurements
yielded similar results.
We classified the ADNI participants in a descriptive unbiased
approach (Jack et al, 2016a) into two different schemes. First, their
biomarker profile, which is defined by the three different pathologic
processes that occur in AD and that a biomarker can measure, that
is: (i) aggregated Ab (A, as defined by CSF Ab1–42); (ii) aggregated
tau (T, as defined by CSF P-tau181P); (iii) neurodegeneration or
neuronal injury (N, as defined by CSF T-tau). We binarized each of
the biomarker group into positive (+, abnormal) or negative (,
normal) based on the reported cut-offs for each of the biomarkers
(Hansson et al, 2018). Levels below 976.6 pg/ml (Ab1–42) or above
21.8 pg/ml (P-tau181P) and 245 pg/ml (T-tau) were categorized as
positive (A+, T+, N+, respectively). To reduce the number of
groups, we merged the aggregated tau (T) and neurodegeneration
(N) groups. If either aggregated tau (T) or neurodegeneration (N)
was abnormal (T+ or N+), participants were classified as TN abnor-
mal (TN+). If both aggregated tau (T) and neurodegeneration (N)
were normal (T and N), participants were classified as TN
normal (TN). Note that in the “healthy control” group, we set the
criteria that both aggregated tau (T) and neurodegeneration (N)
biomarker profile should be normal, so that we ensure that this
group is indeed free of pathology. Importantly, only 54 participants
(5.3% of the total sample) displayed discrepancies between the T
and N biomarker groups. Second, we classified the participants
based on clinical symptoms based on the clinical dementia rating
(CDR) global score (Morris, 1993) into cognitively unimpaired
(CDR = 0), very mild dementia (CDR = 0.5) and mild dementia
(CDR = 1). In the sample studied, there were no participants with
moderate or severe dementia (CDR = 2–3). The combination of both
the biomarker and the clinical classification rendered 12 different
groups that are summarized in Table 3.
Cognition in ADNI participants was assessed by ADNI-Mem,
ADNI-EF, ADAS-Cog 11, ADAS-Cog 13, MMSE and CDR-SB. ADNI-
Mem and ADNI-EF are both composite scores developed by ADNI.
ADNI-Mem is derived from of the following test scores: Rey Audi-
tory Verbal Learning test, Alzheimer’s Disease Assessment Sched-
ule-Cognition (ADAS-Cog), MMSE and Logical Memory (Crane et al,
2012). The ADNI-EF is derived from the following tests: Wechsler
Adult Intelligence Scale—Revised Digit Symbol Substitution, Digit
Span Backwards, Trials A and B, Category Fluency and Clock Draw-
ing (Gibbons et al, 2012).
Hippocampal volumes based on FreeSurfer segmentation and
FDG-PET ROI SUVRs derived from meta-analytically regions of AD-
associated hypometabolism located within the angular gyrus, poste-
rior cingulate and inferior temporal lobe were downloaded from the
ADNI database. The MRI and FDG-PET ROI segmentation has been
described in detail previously (Fischl et al, 2002; Landau et al,
2011). Hippocampal volumes were further adjusted for intracranial
volume using linear regression, following previous recommenda-
tions (Jack et al, 2017).
Ethical considerations
The study was approved by the institutional review board (IRB) of
all participating centres in DIAN and ADNI, as well as our local IRB
(LMU). All study participants (or their relatives) provided written
informed consent.
CSF progranulin (PGRN) measurement
CSF PGRN was measured by an ELISA protocol previously estab-
lished by our group using the MSD Platform (Capell et al, 2011).
The ELISA consists of a Streptavidin-coated 96-well plates (MSD
Streptavidin Gold Plates, cat. no. L15SA); a biotinylated polyclonal
goat anti-human PGRN capture antibody (BAF2420, R&D Systems;
0.2 lg/ml, 25 ll/well); a monoclonal mouse anti-human PGRN
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detection antibody (MAB2420, R&D Systems; 0.25 lg/ml, 25 ll/
well); and a SULFO-TAG-labelled goat polyclonal anti-mouse IgG
secondary antibody (MSD, cat. no. R32AC; 0.5 lg/ml, 25 ll/well).
All antibodies were diluted in 0.5% bovine serum albumin (BSA)
and 0.05% Tween-20 in PBS buffer (pH = 7.4). Recombinant human
PGRN protein (His Tag PGRN—Sino Biological, cat. no. 10826-
H08H) was used as a standard (15.6–2,000 pg/ml). In brief, Strepta-
vidin-coated 96-well plates were blocked overnight at 4°C in block-
ing buffer [0.5% BSA and 0.05% Tween-20 in PBS (pH = 7.4)]. The
plates were next incubated with the capture antibody for 1 h at
room temperature (RT). They were subsequently washed four times
with washing buffer (0.05% Tween-20 in PBS) and incubated for
2 h at RT with the CSF and the internal standard (IS) samples
diluted 1:2.5 in assay buffer [0.25% BSA and 0.05% Tween-20 in
PBS (pH = 7.4)] or the recombinant human PGRN protein for the
standard curve also diluted in assay buffer. CSF samples were
randomly distributed across plates and measured in triplicates
(DIAN samples) or in duplicates (ADNI samples). The operators
were blinded to the clinical information. Plates were again washed
four times with washing buffer before incubation for 1 h at RT with
the detector antibody. After four additional washing steps, plates
were incubated with the secondary antibody for 1 h in the dark.
Last, plates were washed four times with washing buffer followed
by two washing steps in PBS. The electrochemical signal was devel-
oped by adding MSD read buffer T (cat. no. R-92TC) and the light
emission measured using the MESO QuickPlex SQ 120. The ELISA
showed good accurate results in the spike recovery (98%) experi-
ments and minimal measurement variation (CV = 4%) between
freeze–thaw cycles (nine cycles).
The measurement of all the DIAN samples was performed in a
single day (22/11/2016), and three CSF samples (internal stan-
dards, IS) were loaded in all plates. All IS used in this study
consisted of pooled CSFs from diagnostic clinical routine leftovers
from the Ludwig-Maximilians-Universita¨t Mu¨nchen (LMU) Depart-
ment of Neurology (Munich, Germany). All patients gave their
written consent, and the study was approved by the local IRB. The
interplate coefficient of variation (CV) for each of the IS was 3.6,
5.4 and 6.7%. The mean intraplate CV was 2.1%, and all replicate
measures had a CV ≤ 15%. The raw values are provided as pg/ml.
The measurements of the ADNI samples were performed on four
different days (between the 27/11/2017 and 06/12/2017). Four CSF-
IS samples were loaded in all plates. The interplate CV for each of
the IS was 4.3, 3.8, 3.4 and 5.4%. The mean intraplate CV was
2.2%, and all replicate measures had a CV ≤ 15%. Given that the
ADNI measurements were done in several days, we corrected the
raw measurements based on values of the four IS that were loaded
on all plates. The concentration of each IS in an individual plate
(plate x) was expressed as a percentage of the mean concentration
across all plates as follows:
a1 (%) in plate x = [(concentration of IS1 in plate x)/(mean
concentration of IS1 in all plates)] × 100
a2 (%) in plate x = [(concentration of IS2 in plate x)/(mean
concentration of IS2 in all plates)] × 100
a3 (%) in plate x = [(concentration of IS3 in plate x)/(mean
concentration of IS3 in all plates)] × 100
a4 (%) in plate x = [(concentration of IS4 in plate x)/(mean
concentration of IS4 in all plates)] × 100
The mean of the percentages (Ax) for all the IS (a1, a2, a3, a4) in
plate x was calculated, and the following correction factor was
computed for each individual plate:
Correction factor for plate x ¼ 100=Ax
The raw values were multiplied by the correction factor of the
corresponding plate; the corrected values are provided as the vari-
able “MSD_PGRNCORRECTED” in the ADNI database. Due to the
low interplate CV, the corrected and raw PGRN values in the ADNI
sample are highly correlated (Spearman q = 0.985; P < 0.0001).
The mean CSF PGRN level of our MSD-based assay (1,007 pg/ml)
was similar to that published with other assays (Huchtemann et al,
2015; Zhou et al, 2015a; Berghoff et al, 2016; Meeter et al, 2016;
Kimura et al, 2017; Schreiber et al, 2018), albeit lower than those
measured by the more widely used commercial assay from Adipogen
(Ghidoni et al, 2008; De Riz et al, 2010; Vercellino et al, 2011;
Nicholson et al, 2014; Morenas-Rodrı´guez et al, 2015; Feneberg
et al, 2016; Molgaard et al, 2016; Willemse et al, 2016; Wilke et al,
2017). We therefore compared our MSD-based ELISA with that from
Adipogen (cat. no. AG-45A-0018YEK-KI01, Seoul, Korea). We
prepared 39 different CSF pool samples from leftovers of the LMU
Department of Neurology, as described above. We measured these
CSF samples simultaneously in both the MSD-based and the
Adipogen assays, following the manufacturer’s instructors, and each
sample in duplicate. The standard curves for each of the assays are
shown in Appendix Fig S1A and B. As expected, the mean levels
of CSF PGRN were lower in the MSD-based assay (mean = 1430 pg/
ml, SD = 220) compared to the Adipogen assay (mean = 4,400
pg/ml, SD = 900), but they were highly correlated between them
(Spearman q = 0.74; P < 0.0001; Appendix Fig S1C).
CSF sTREM2 measurement
CSF sTREM2 measurements from the DIAN study were previously
reported (Sua´rez-Calvet et al, 2016a,b) and are expressed relative to
an IS. Measurements of the ADNI samples were done with the same
ELISA protocol with minor changes. Briefly, the assay is based on
the MSD platform and it is comprehensively described in previous
publications (Kleinberger et al, 2014; Sua´rez-Calvet et al, 2016a,b).
The assay consists of a Streptavidin-coated 96-well plates (MSD
Streptavidin Gold Plates, cat. no. L15SA); a biotinylated polyclonal
goat IgG anti-human TREM2 antibody (R&D Systems, cat. no.
BAF1828; 0.25 lg/ml, 25 ll/well) as capture antibody, which is
raised against amino acids 19-174 of human TREM2; a monoclonal
mouse IgG anti-human TREM2 antibody (Santa Cruz Biotechnology,
B-3, cat. no. sc373828; 1 lg/ml, 50 ll/well) as a detection antibody,
which is raised against amino acids 1–160 of human TREM2; and a
SULFO-TAG-labelled goat polyclonal anti-mouse IgG secondary anti-
body (MSD, cat. no. R32AC; 0.5 lg/ml, 25 ll/well). All antibodies
were diluted in 1% BSA and 0.05% Tween-20 in PBS buffer
(pH = 7.4). Recombinant human TREM2 protein (Ho¨lzel Diagnos-
tika, cat. no. 11084-H08H), corresponding to the extracellular
domain of human TREM2 (amino acids 19–174), was used as a stan-
dard (62.5–8,000 pg/ml). In brief, Streptavidin-coated 96-well plates
were blocked overnight at 4°C in blocking buffer [3% bovine serum
albumin (BSA) and 0.05% Tween-20 in PBS (pH = 7.4); 300 ll/
well]. The plates were next incubated with the capture antibody for
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1 h at RT. They were subsequently washed four times with washing
buffer (200 ll/well; 0.05% Tween-20 in PBS). Thereafter, the
recombinant human TREM2 protein (standard curve), the blanks,
and the CSF and the internal standard (IS) samples (duplicates; dilu-
tion factor: 4) were diluted in assay buffer [0.25% BSA and 0.05%
Tween-20 in PBS (pH = 7.4)] supplemented with protease inhibitors
(Sigma; Cat. # P8340) and incubated (50 ll/well) for 2 h at RT. This
dilution was previously selected because it showed the best recov-
ery and linearity performance (Kleinberger et al, 2014). Plates were
again washed four times with washing buffer before incubation for
1 h at RT with detection antibody. After four additional washing
steps, plates were incubated with SULFO-tag conjugated secondary
antibody for 1 h in the dark at RT. Last, plates were washed four
times with washing buffer followed by two washing steps in PBS.
The electrochemical signal was developed by adding 150 ll/well
MSD read buffer T (cat. no. R-92TC) and the light emission
measured using the MESO QuickPlex SQ 120. Raw values are
provided as pg/ml.
All CSF samples were distributed randomly across plates,
measured in duplicate and simultaneously to CSF PGRN (i.e.
between 27/11/2017 and 06/12/2017). The mean intraplate CV was
3.1%, and all duplicate measures had a CV < 15%. Alike the CSF
PGRN ELISA, four CSF IS samples were loaded in all plates. The
interplate CV for each of the IS was 11.4, 12.2, 10.5 and 7.1%. We
corrected the raw measurements based on values of the four IS that
were loaded on all plates in a similar manner as in CSF PGRN
measurements. Consequently, the corrected values were used and
are available in the ADNI database as variables “MSD_sTREM2COR-
RECTED”.
Statistical analysis
In both DIAN and ADNI samples, we only included in our study
participants that had the following data available: age, gender and
the three AD CSF core biomarkers (Ab1–42, T-tau, P-tau181P). Within
each of the samples, we determined the CSF PGRN outliers, as
defined as values differing 3 standard deviations from the mean (3
outliers in the DIAN sample and 11 in the ADNI sample). In order to
rule out that our results are not driven by extreme values, all the
analysis described in the main text are performed without these
outliers. Nevertheless, including them did not affect the main results
(as shown in the main text and in Appendix Tables S1, S3, S5, S6
and S8). In the DIAN sample, CSF PGRN followed a normal distribu-
tion as assessed by visual inspection of histogram and after testing
by Kolmogorov–Smirnov test (P = 0.062). In contrast, CSF PGRN in
ADNI did not follow a normal distribution (Kolmogorov–Smirnov
test, P = 0.0001). After a log10 transformation, it followed a normal
distribution (Kolmogorov–Smirnov test, P = 0.200). All the statisti-
cal analyses in the ADNI sample were hence performed with the
log10-transformed values.
The data from the DIAN sample (Data Freeze 9) were studied in
a similar approach to that we previously applied (Sua´rez-Calvet
et al, 2016a,b). In brief, comparisons of demographic, clinical and
biochemical data between NC and MC were performed by Pearson’s
chi-square tests or t-tests, as appropriate. A linear regression analy-
sis was used to test the effect of the mutation status, age, gender
and APOE e4 status in the levels of CSF PGRN (Appendix Table S1).
In additional linear effects models, we compared the levels of CSF
PGRN between carriers of the three mutated genes (i.e. PSEN1,
PSEN2 and APP).
In order to test how CSF PGRN levels change as a function of
EYO (as shown in Table 2 and Fig 2), we used a similar approach
to that previously published (Bateman et al, 2012; Fagan et al,
2014; Sua´rez-Calvet et al, 2016a,b). We constructed a linear mixed
model with mutation status, EYO (and its interaction with mutation
status) and gender as fixed effects and family affiliation as random
effect. Next, we performed a polynomial regression analysis includ-
ing EYO quadratic (EYO2) and cubic (EYO3) terms and their inter-
actions with mutation status. We determined the model that best
fitted the data by forward selection of the predictors, and the final
model was chosen based on the Akaike information criterion (AIC;
a lower AIC indicating a better fit; see Appendix Table S2). For CSF
PGRN, the linear model (first-order EYO) showed the best fit. In
previous studies, we used linear mixed-effects models with family
membership as a random effect to adjust for differences in
biomarker levels between families. Here, we found no significant
differences in CSF PGRN levels between families (F93,114 = 1.04,
P = 0.426) and we therefore used simple linear regression in all the
following analysis.
We computed the estimated levels of CSF PGRN at each 5-year
interval of EYO based on the established regression models, and we
determined the group differences between MC and NC for each 5-
year EYO interval by t-tests, as done in previous DIAN studies (Bate-
man et al, 2012; Fagan et al, 2014; Sua´rez-Calvet et al, 2016a,b).
Comparisons between MC and NC were restricted at EYO ranging
from 25 to +10, due to the low number of subjects at more extreme
values of EYO.
In order to represent the progression of CSF PGRN throughout
the evolution of the disease and compare it with other biomarkers
and cognitive measures, we followed the approach of previous
DIAN studies (Bateman et al, 2012; Sua´rez-Calvet et al, 2016a,b);
that is, the predicted difference between MC and NC at each EYO
generated by the same final linear mixed-effects model described
above was divided by the standard deviation of clinical, cognitive,
imaging and biochemical measures of the pooled sample, so that all
variables were in a standardized and comparable scale (Fig 2B,
Appendix Table S2). These figures were built with SAS software
(SAS Institute).
We compared CSF PGRN levels between NC and MC in different
clinical stages (determined by global CDR) in an analysis of covari-
ance (ANCOVA) controlling for age, gender, APOE e4 and educa-
tion, followed by post hoc least significant difference (LSD) for pair-
wise comparisons. Individuals falling into CDR = 1 to CDR = 3 were
grouped together due to the low number of subjects in these stages.
In ADNI, demographic, clinical and biochemical data group
comparisons were performed by one-way ANOVA or Pearson’s chi-
square tests, as appropriate. To test whether CSF PGRN changed
across the Alzheimer’s continuum, we applied an ANCOVA includ-
ing the biomarker-defined stages of AD, gender and APOE e4 status
as fixed effects and age as covariate, followed by Bonferroni
corrected pair-wise post hoc comparisons. An additional analysis
was performed adding the GRN rs5848 genotype as a covariate. A
similar approach was used for comparisons between biomarker
categories shown in Fig EV1A.
To study the associations between CSF PGRN and cognitive and
functional scores, we applied three linear regression models. Model
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1 was unadjusted, Model 2 included age, gender, APOE e4 and
education as covariates, and Model 3 included the former covariates
and also CSF Ab1–42 and CSF T-tau.
The association between CSF PGRN and temporo-parietal FDG-
PET and total hippocampal volume was tested with a linear regres-
sion adjusted for age, gender, APOE e4 and education. Analyses
including hippocampal volume were adjusted for intracranial
volume.
The diagnostic value of CSF PGRN to discriminate AD (ADAD or
late-onset AD) from controls was tested with a receiver operating
characteristic (ROC) analysis. We computed areas under the curve
(AUC), and we tested whether they were significantly different from
the null hypothesis that the AUC equals 0.50, which corresponds to
a random test.
Finally, the association between CSF PGRN and CSF sTREM2
and the CSF core biomarkers for AD (T-tau, P-tau181P, Ab1–42) was
studied with a linear model adjusted for age, gender and APOE e4
status. The analysis was performed stratifying for the mutation
status (DIAN) or classifying the subjects in the healthy controls,
Alzheimer’s continuum or SNAP categories (ADNI). The standard-
ized regression coefficients (b) are reported. In order to rule out that
the associations were driven by extreme values, we performed the
analysis both including and excluding biomarker outliers (defined
as AD CSF core biomarkers 3 standard deviations below or
above the group mean) and the analysis yielded similar results
(Appendix Table S8).
Statistical analysis was performed in SPSS IBM, version 20.0,
statistical software and the free statistical software R (http://www.r-
project.org/). Figures were built using GraphPad Prism or R. All
tests were two-tailed, with a significance level of a = 0.05.
Expanded View for this article is available online.
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